Zenlabs Ethica Limited (BOM:530697)

India flag India · Delayed Price · Currency is INR
17.37
-0.91 (-4.98%)
At close: Mar 30, 2026
Market Cap113.08M -47.4%
Revenue (ttm)493.24M -8.3%
Net Income-18.46M
EPS-2.88
Shares Out6.51M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,182
Average Volume9,109
Open18.27
Previous Close18.28
Day's Range17.37 - 18.27
52-Week Range16.50 - 39.20
Beta-1.04
RSI39.46
Earnings DateMay 12, 2026

About Zenlabs Ethica

Zenlabs Ethica Limited markets and distributes pharmaceutical products primarily in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; soaps; and other pharmaceutical drugs. The company is... [Read more]

Industry Drugs, Drug Proprietaries, and Druggists' Sundries
Founded 1993
Employees 65
Stock Exchange Bombay Stock Exchange
Ticker Symbol 530697
Full Company Profile

Financial Performance

In fiscal year 2025, Zenlabs Ethica's revenue was 514.23 million, a decrease of -12.19% compared to the previous year's 585.63 million. Earnings were 2.69 million, a decrease of -36.09%.

Financial Statements